Cargando…
Plasma Pentraxin 3 Levels Do Not Predict Coronary Events but Reflect Metabolic Disorders in Patients with Coronary Artery Disease in the CARE Trial
Chronic inflammation closely associates with obesity, metabolic syndrome, diabetes mellitus, and atherosclerosis. Evidence indicates that the immunomodulator pentraxin 3 (PTX3) may serve as a biomarker of these cardiometabolic disorders, but whether PTX3 predicts cardiovascular complications is unkn...
Autores principales: | Miyazaki, Tetsuro, Chiuve, Stephanie, Sacks, Frank M., Ridker, Paul M., Libby, Peter, Aikawa, Masanori |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3976379/ https://www.ncbi.nlm.nih.gov/pubmed/24705587 http://dx.doi.org/10.1371/journal.pone.0094073 |
Ejemplares similares
-
Associations between pentraxin 3 and severity of coronary artery disease
por: Liu, Hua, et al.
Publicado: (2015) -
Postmortem plasma pentraxin 3 is a useful marker of fatal acute coronary syndrome
por: Tojo, Misa, et al.
Publicado: (2019) -
Prognostic Value of Plasma Pentraxin-3 Levels in Patients with Stable Coronary Artery Disease after Drug-Eluting Stent Implantation
por: Haibo, Liu, et al.
Publicado: (2014) -
Pentraxin 3 (PTX3) promoter methylation associated with PTX3 plasma levels and neutrophil to lymphocyte ratio in coronary artery disease
por: Guo, Tang-Meng, et al.
Publicado: (2016) -
Serum Pentraxin-3 Level in Patients Who Underwent Coronary Angiography and Relationship with Coronary Atherosclerosis
por: Nerkiz, Polat, et al.
Publicado: (2015)